Planet X Town Hall

ilinda - SURVIVAL HEALTH => All Medical Marijuana, Hemp, CBD Oil and Psilocybin Mushroom Topics => Topic started by: Yowbarb on June 14, 2017, 01:06:28 PM

Title: THE SACRED PLANT/info from Global Moderator GenericUser
Post by: Yowbarb on June 14, 2017, 01:06:28 PM
Yowbarb Note:
Global Moderator GenericUser sent me this video -  The Sacred Plant
Title: Re: THE SACRED PLANT/info from Global Moderator GenericUser
Post by: ilinda on February 20, 2019, 03:56:47 PM
The attached screenshot is from one episode of The Sacred Plant series, and it is just a small sampling of some of the offerings from one dispensary.  IIRC, this dispensary is in CA.  Prices might seem high, but when you realize the amount of plant needed to make just one bottle of oil, the cost is probably reasonable.
Title: Re: THE SACRED PLANT/info from Global Moderator GenericUser
Post by: R.R. Book on February 21, 2019, 12:21:54 PM
That marquis reminds me that I heard recently that the federal government is exploring a pretext to begin regulating CBD oil.  I forget on what grounds.

Has anyone heard about this?
Title: Re: THE SACRED PLANT/info from Global Moderator GenericUser
Post by: ilinda on February 21, 2019, 03:42:01 PM
I don't know on what grounds, but the CDC does hold a patent on CBD, or at least some part of the U.S.Fed.Gov. does, and in the patent, claims it has anti-inflammatory effects, or something like that. 

However, there is something in the federal law that mandates certain substances must be Schedule I or II or whatever, if they have certain known effects, but also have no medical uses.  The problem is that medical use for CBD has been shown many times over, as well as have uses for medical m. 

They are caught between a rock and a hard place because while they did finally legalize cbd oil, but have not legalized, at the federal level, Cannabis sativa, but that plant also has medical uses, by itself, as well as some of the entities isolated from the plant.

Maybe this was their plan all along:  legalize cbd, then tax the hell out of it, and make certain only the biggest players (think BigPharma) will get to market it.  People had better be learning how to grow m. if they don't already know how.
Title: Re: THE SACRED PLANT/info from Global Moderator GenericUser
Post by: Yowbarb on February 21, 2019, 11:59:37 PM
Very true, survival communities need to know how to produce their own CBD and also the smoking stuff for terminally ill people.
I'm not real big on drugs but am live and let live on the more benign things. Also I am all for medical marijuana and signed the petition to legalize it in the state of Florida, many years ago, then it got on the ballot and I voted for Yes it.
I do know for a fact it has very strong pain-relieving properties.
Title: Re: THE SACRED PLANT/info from Global Moderator GenericUser
Post by: Yowbarb on February 22, 2019, 12:04:12 AM
Old Topic to add to,,3396.msg100693.html#msg100693

SURVIVALIST HEAL THYSELF / Medical Marijuana - Charlie Little's Topic
Title: Re: THE SACRED PLANT/info from Global Moderator GenericUser
Post by: Yowbarb on August 17, 2019, 10:00:12 AM

What Does the Future Look Like For CBD Products In the United States?

CBD is now available in all 50 states of America — to varying degrees. Most citizens can access the supplement in-store legally but may be hard-pressed to find it in some of the stricter states requiring medical cards.
Title: Re: THE SACRED PLANT/info from Global Moderator GenericUser
Post by: Yowbarb on August 17, 2019, 10:09:21 AM
(This article is about CBD oil. cannabidiol ) Posting some main excerpts. I find this very exciting:
The findings suggest that “cannabidiol can help re-adjust brain activity to normal levels,” according to a King’s College London press statement.

“This was not a treatment trial, but it does show that CBD changes certain brain structures in a direction that indicates improvement,” Grant said.

Helping the brain ‘reset’
While big gaps remain in knowledge of the brain mechanisms involved in diseases such as schizophrenia, Grant says the King’s College London study suggests that the cannabinoid “may normalize the connectors or ‘cross talk’ in regions of the brain associated with schizophrenia.”

Cannabis Compound May Help Reduce Symptoms of Psychosis

Experts say cannabidiol may be able to help “reset” the brains of people who have conditions such as schizophrenia and bipolar disorder.

A possible preventive tool
Bhattacharyya and his colleagues are currently undertaking a large-scale study to determine whether CBD can be used to prevent young people at risk of psychosis from developing mental health disorders.

“There is an urgent need for a safe treatment for young people at risk of psychosis,” Bhattacharyya said. “One of the main advantages of cannabidiol is that it is safe and seems to be very well-tolerated, making it in some ways an ideal treatment. If successful, this trial will provide definitive proof of cannabidiol’s role as an antipsychotic treatment and pave the way for use in the clinic.”

In the United States, 31 states and the District of Columbia — but not the federal government — have decriminalized or legalized marijuana for medical use.

Smoking or ingesting marijuana delivers a dose of both CBD and THC.

However, compounds containing only CBD are also offered for sale in many states where medical marijuana use has been legalized.

continue reading:

Title: Re: THE SACRED PLANT/info from Global Moderator GenericUser
Post by: ilinda on August 17, 2019, 10:54:59 AM
It is important to note results of a Univ. of PA study on integrity of cbd products, so Let The Buyer Beware..

 News Release
Penn Study Shows Nearly 70 Percent of Cannabidiol Extracts Sold Online Are Mislabeled

Mislabeling may lead to adverse effects for patients, including children with epilepsy
November 07, 2017

PHILADELPHIA – In recent years, there has been an increased interest in the medicinal use of Cannabidiol (CBD), a chemical that naturally occurs the in cannabis plant (aka “marijuana”). There is interest in CBD as a medicine because there is some evidence that it has medical benefits, but it does not make people feel “high” and there is no indication that CBD, by itself, is abused. Recent research has shown potential therapeutic effects of CBD for young children with rare seizure disorders, and patients in states where cannabis or CBD have been legalized report using it for a variety of health conditions. Business experts estimate that the market for CBD products will grow to more than $2 billion in consumer sales within the next three years. While interest in this area continues to grow, little has been done to ensure regulation and oversight of the sale of products containing CBD. The primary reason for this is that CBD is currently classified as a Schedule I controlled dangerous substance by the DEA, despite having been legalized for medicinal use in many states. Thus, many people do not have access to stores that sell CBD products and instead rely on online retailers to purchase CBD products.

A new study by a Penn Medicine researcher, published this week in JAMA, found that nearly 70 percent of all cannabidiol products sold online are either over or under labeled, causing potential serious harm to its consumers. Marcel Bonn-Miller, PhD, an adjunct assistant professor of Psychology in Psychiatry and the lead author on the study, believes the mislabeling of cannabidiol products is a direct result of inadequate regulation and oversight.

“The big problem, with this being something that is not federally legal, is that the needed quality assurance oversight from the Food and Drug Administration is not available. There are currently no standards for producing, testing, or labeling these oils,” Bonn-Miller said. “So, right now, if you buy a Hershey bar, you know it has been checked over; you know how many calories are in it, you know it has chocolate as an ingredient, you know how much chocolate is in there. Selling these oils without oversight, there is no way to know what is actually in the bottle. It’s crazy to have less oversight and information about a product being widely used for medicinal purposes, especially in very ill children, than a Hershey bar.”

For a month, Bonn-Miller and his team of researchers conducted internet searches to identify and purchase CBD products available for online retail purchase that included CBD content on the packaging. The team purchased and analyzed 84 products from 31 different companies and found that more than 42 percent of products were under-labeled, meaning that the product contained a higher concentration of CBD than indicated. Another 26 percent of products purchased were over-labeled, meaning the product contained a lower concentration of CBD than indicated. Only 30 percent of CBD products purchased contained an actual CBD content that was within 10% of the amount listed on the product label. While studies have not shown that too much CBD can be harmful, products containing either too little or too much CBD than labeled could negate potential clinical benefit to patients. Further, the variability across products may make it troublesome for patients to get a reliable effect.

“People are using this as medicine for many conditions (anxiety, inflammation, pain, epilepsy),” Bonn-Miller explained. “The biggest implication is that many of these patients may not be getting the proper dosage; they’re either not getting enough for it to be effective or they’re getting too much.”

According to Bonn-Miller, a number of products also contained a significant amount of THC—the chemical compound in cannabis responsible for making a person feel “high” — which has been shown cause cognitive impairment and other adverse health effects. “This is a medication that is often used for children with epilepsy, so parents could be giving their child THC without even knowing it,” he said.

In a previous study, Bonn-Miller and colleagues analyzed cannabinoid dose and label accuracy in edible medical cannabis products and found similar discrepancies. He hopes this and future studies will call attention to the impact of inconsistent cannabis product labelling.

“Future research should be focused on making sure people are paying attention to this issue and encouraging regulation in this rapidly expanding industry.”

Other authors on the paper include Mallory Loflin of the Veterans Affairs San Diego Health Care System, Brian Thomas of RTI International, Jahan Marcu of Americans for Safe Access, Travis Hyke of Palo Alto University, and Ryan Vandrey of Johns Hopkins University.

This study was supported by funding from the Institute for Research on Cannabinoids (IROC).
Topic: Public Health
Title: Re: THE SACRED PLANT/info from Global Moderator GenericUser
Post by: ilinda on December 22, 2019, 02:18:39 PM
Food for Thought from